Experimental Medicine Network

Seeking to establish a European consortium focused on developing, validating, and maintaining state-of-the-art human experimental medicine models to accelerate psychiatric drug discovery and development. By bridging the gap between animal and human studies, it aims to support Phase 1 and Phase 2 clinical trials. The Network initially focuses on schizophrenia, depression, anxiety, and cognition, with the goal of creating models that are both academically rigorous and industry-ready.

History

The Experimental Medicine ECNP Network was founded in 2013 as part of an initiative to build a European-wide consortium of academic centres dedicated to advancing human experimental medicine models in psychiatry. Recognising the crucial role of these models in bridging preclinical and clinical studies, the network was designed to foster collaboration between academia, industry, and SMEs. 

Our global Network is actively working on developing trans-diagnostic biomarkers that will support the discovery and development of novel treatments in psychiatry. Examples of successful network-initiated activities include the development of a quantitative biological approach to understanding and classifying neuropsychiatric diseases (e.g., PRISM), and the validation of novel (e.g., task-based) measurements of anhedonia. More recently, the Network has been developing work packages aimed at improving the prediction of treatment response with fast-acting antidepressants. With these initiatives, we aim to accelerate and maximize the benefits of novel treatments for those most in need of them.

Dennis Hernaus, the Netherlands.
Members
Name Organisation City Country
Celso Arango Hospital General Universitario Gregorio Marañon Madrid Spain
Derek Buhl Abbvie Cambridge, Massachusetts USA
Philippe Danjou Biotrial Rennes France
Gerard Dawson P1vital Wallingford, Oxfordshire United Kingdom
Caroline Golden Novartis Basel Switzerland
Oliver  Grimm  Johann Wolfgang Goethe University Frankfurt am Main Germany
Catherine Harmer University of Oxford Oxford United Kingdom
Dennis Hernaus Maastricht University Maastricht The Netherlands
Martien Kas University of Groningen Groningen The Netherlands
Gitte M. Knudsen Rigshospitalet Copenhagen Denmark
Mitul Mehta  IoPPN - King's College London London United Kingdom
Carmen Moreno Hospital General Universitario Gregorio Marañon Madrid Spain
Brian Murphy Cumulus Neuroscience Belfast United Kingdom
David Nutt Imperial College London London United Kingdom
Georgios Papazisis Aristotle University of Thessaloniki Thessaloniki Greece
Brenda Penninx VU University Amsterdam Amsterdam The Netherlands
Andreas Reif University Hospital Frankfurt Frankfurt Germany
Alessandro Serretti University of Bologna Bologna Italy
Paul Stokes IoPPN - King's College London London United Kingdom
Elizabeth Tunbridge Boehringer Ingelheim International GmbH Biberach an der Riß Germany
Daniel Umbricht Gilgamesh Pharmaceuticals NY USA
Nic van der Wee Leiden University Medical Center Leiden The Netherlands